Loading clinical trials...
Loading clinical trials...
Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment
The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.
Treatment, Parallel Assignment, Open Label, Non-Randomized, Single Dose Adaptive Design, Pharmacokinetics Study
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Orlando Clinical Research Center
Orlando, Florida, United States
Davita Clinical Research
Minneapolis, Minnesota, United States
Start Date
September 1, 2012
Primary Completion Date
June 1, 2013
Completion Date
June 1, 2013
Last Updated
November 16, 2015
58
ACTUAL participants
Daclatasvir
DRUG
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions